Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial (2017)
- Authors:
- Autor USP: BURDMANN, EMMANUEL DE ALMEIDA - FM
- Unidade: FM
- DOI: 10.1159/000485326
- Subjects: HEMOGLOBINAS; DOENÇAS CARDIOVASCULARES; INSUFICIÊNCIA RENAL CRÔNICA; DIABETES MELLITUS; FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: American journal of nephrology
- ISSN: 0250-8095
- Volume/Número/Paginação/Ano: v. 46, n. 6, p. 488-497, 2017
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
CAUSLAND, Finnian R. Mc et al. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American journal of nephrology, v. 46, n. 6, p. 488-497, 2017Tradução . . Disponível em: https://doi.org/10.1159/000485326. Acesso em: 02 dez. 2025. -
APA
Causland, F. R. M., Claggett, B., Pfeffer, M. A., Burdmann, E. de A., Eckardt, K. -U., Levey, A. S., et al. (2017). Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American journal of nephrology, 46( 6), 488-497. doi:10.1159/000485326 -
NLM
Causland FRM, Claggett B, Pfeffer MA, Burdmann E de A, Eckardt K-U, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial [Internet]. American journal of nephrology. 2017 ; 46( 6): 488-497.[citado 2025 dez. 02 ] Available from: https://doi.org/10.1159/000485326 -
Vancouver
Causland FRM, Claggett B, Pfeffer MA, Burdmann E de A, Eckardt K-U, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial [Internet]. American journal of nephrology. 2017 ; 46( 6): 488-497.[citado 2025 dez. 02 ] Available from: https://doi.org/10.1159/000485326 - Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
- Extracorporeal Treatment for Lithium Poisoning: systematic Review and Recommendations from the EXTRIP Workgroup
- Peritoneal Dialysis in Acute Kidney Injury: Lessons Learned and Applied
- Acute kidney injury: global health alert
- Acute kidney injury: global health alert
- Predictive usefulness of unirary biomarkers for the identification of cyclosporine A induced nephrotoxicity in a rat model
- Cyclic Direct Radionuclide Cystography in the Diagnosis and Characterization of Vesicoureteral Reflux in Children and Adults
- Association of magnesium abnormalities at intensive care unit admission with kidney outcomes and mortality: a prospective cohort study
- Empatia em estudantes de Medicina: efeitos de um programa de gerenciamento do estresse
- Censo de Diálise do Brasil de 2009
Informações sobre o DOI: 10.1159/000485326 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
